一般社団法人日本呼吸器学会 公式サイト
日本呼吸器学会英文誌 Respiratory Investigation
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集 検索用
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集 全文PDF

Abstract

Full Text of PDF Full Text of PDF (618k)
Article in Japanese

Topics Series Cell and molecular biology

Next-generation sequencer-based lung cancer genomics and its translation to precision medicine

Kuniko Sunamia,b  Takashi Kohnoa 

aDivision of Genome Biology, National Cancer Center Research Institute
bDepartment of Thoracic Oncology, National Cancer Center Hospital

ABSTRACT

Identification of druggable oncogene aberrations driving lung carcinogenesis has facilitated personalized therapy of lung cancer. The identification has been achieved by recent progress of large-scale genome analysis technologies. Notably, oncogenic RET, NRTK1, and NRG1 fusions were identified as novel therapeutic targets in lung adenocarcinoma by next-generation sequencer-based genome/transcriptome analyses. A nationwide genomic screening system was established in Japan for developing personalized therapy of advanced non-small cell lung cancer with RET fusion. In this chapter, we describe the current challenge in developing personalized therapy of lung cancer.

KEYWORDS

Next-generation sequencer  Personalized therapy  Driver gene aberration  Clinical sequencing 

AJRS, 3(5): 636-642, 2014

Google Scholar